Heart failure in patients with atrial fibrillation: Insights from Polish part of the EORP-AF general long-term registry.

Atrial fibrillation Heart failure Mid-range ejection fraction Preserved ejection fraction Reduced ejection fraction

Journal

ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191

Informations de publication

Date de publication:
Feb 2023
Historique:
revised: 20 06 2022
received: 28 12 2020
accepted: 18 08 2022
pubmed: 24 11 2022
medline: 26 1 2023
entrez: 23 11 2022
Statut: ppublish

Résumé

This study aimed to determine the impact of heart failure (HF) on clinical outcomes in patients with atrial fibrillation (AF). We analysed data from Polish participants of the EURObservational Research Programme-AF General Long-Term Registry. The primary endpoint was all-cause death, and the secondary endpoints included hospital readmissions, cardiovascular (CV) interventions, thromboembolic and haemorrhagic events, rhythm control interventions, and other CV or non-CV diseases development during one-year follow up. Overall, 688 patients with available data on HF were included into analysis; 51% (n = 351) had HF; of these 48% (n = 168) had reduced ejection fraction (HFrEF), 22% (n = 77) mid-range EF (HFmrEF), and 30% (n = 106) preserved EF (HFpEF). Compared with patients without HF, those with HF had higher mortality rate (aHR 5.61; 95% CI 1.94-16.22, P < 0.01). Patients with HF (vs. without HF) had more often CV interventions (10% vs. 5.4%, P = 0.046) and events (14% vs. 7.1%, P = 0.02), and had less often atrial arrhythmia-related hospital admissions (6.8% vs. 15%, P < 0.01). Over follow-up, patients with HFmrEF and HFpEF had similar mortality rate versus HFrEF (aHR 0.45, 95% CI 0.13-1.57, P = 0.45 for HFmrEF and aHR 0.54, 95% CI 0.20-1.48, P = 0.54 for HFpEF). Mortality rate was similar among rhythm versus rate control group (aHR 0.34; 95% CI 0.10-1.16; P = 0.34). AF patients with HF have greater mortality rate and more CV interventions/events. No statistically significant difference in long-term outcomes between patients with HFrEF, HFmrEF, and HFpEF highlights the need to develop therapeutic strategies targeting functional status and survival for patients with HF and AF.

Identifiants

pubmed: 36415165
doi: 10.1002/ehf2.14130
pmc: PMC9871703
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

637-649

Informations de copyright

© 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

Références

Circ Heart Fail. 2012 Mar 1;5(2):191-201
pubmed: 22361078
Circulation. 2022 Jun 7;145(23):1693-1704
pubmed: 35313733
Eur Heart J. 2006 Apr;27(8):936-41
pubmed: 16399778
J Am Heart Assoc. 2013 Feb 01;2(1):e005694
pubmed: 23525446
ESC Heart Fail. 2023 Feb;10(1):637-649
pubmed: 36415165
Eur J Heart Fail. 2016 Aug;18(8):891-975
pubmed: 27207191
Circulation. 2003 Jun 17;107(23):2920-5
pubmed: 12771006
Europace. 2014 Mar;16(3):308-19
pubmed: 24351881
N Engl J Med. 2008 Jun 19;358(25):2667-77
pubmed: 18565859
J Am Coll Cardiol. 2013 May 7;61(18):1894-903
pubmed: 23500267
N Engl J Med. 2018 Feb 01;378(5):417-427
pubmed: 29385358
Europace. 2018 May 1;20(5):747-757
pubmed: 29016832
Circ Arrhythm Electrophysiol. 2014 Feb;7(1):31-8
pubmed: 24382410
JACC Heart Fail. 2017 Jan;5(1):44-52
pubmed: 28034376
Circ J. 2009 Oct;73(10):1893-900
pubmed: 19644216
Int J Cardiol. 2016 Jan 15;203:660-6
pubmed: 26580351
JACC Heart Fail. 2016 Nov;4(11):870-880
pubmed: 27614940
Circulation. 2016 Feb 2;133(5):484-92
pubmed: 26746177
Eur J Heart Fail. 2012 Mar;14(3):295-301
pubmed: 22294759
Circulation. 2004 Mar 30;109(12):1509-13
pubmed: 15007003
Eur J Heart Fail. 2014 Dec;16(12):1317-22
pubmed: 25371247
Kardiol Pol. 2016;74(3):251-61
pubmed: 26365943
Am J Cardiol. 2017 Jun 1;119(11):1763-1769
pubmed: 28416199
Europace. 2016 Nov;18(11):1609-1678
pubmed: 27567465
J Atr Fibrillation. 2019 Feb 28;11(5):2128
pubmed: 31139301
Eur J Intern Med. 2011 Oct;22(5):448-55
pubmed: 21925051
Arch Intern Med. 2012 Jul 9;172(13):997-1004
pubmed: 22664954
N Engl J Med. 2002 Dec 5;347(23):1825-33
pubmed: 12466506
JACC Heart Fail. 2017 Aug;5(8):565-574
pubmed: 28711451

Auteurs

Monika Budnik (M)

First Department of Cardiology, Medical University of Warsaw, Warsaw, Poland.

Monika Gawałko (M)

First Department of Cardiology, Medical University of Warsaw, Warsaw, Poland.
Institute of Pharmacology, West German Heart and Vascular Centre, University Duisburg-Essen, Duisburg, Germany.
Department of Cardiology, Maastricht University Medical Centre and Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands.

Piotr Lodziński (P)

First Department of Cardiology, Medical University of Warsaw, Warsaw, Poland.

Agata Tymińska (A)

First Department of Cardiology, Medical University of Warsaw, Warsaw, Poland.

Krzysztof Ozierański (K)

First Department of Cardiology, Medical University of Warsaw, Warsaw, Poland.

Marcin Grabowski (M)

First Department of Cardiology, Medical University of Warsaw, Warsaw, Poland.

Michał Peller (M)

First Department of Cardiology, Medical University of Warsaw, Warsaw, Poland.

Anna Wancerz (A)

First Department of Cardiology, Medical University of Warsaw, Warsaw, Poland.

Marek Kiliszek (M)

Department of Cardiology and Internal Diseases, Military Institute of Medicine, Warsaw, Poland.

Grzegorz Opolski (G)

First Department of Cardiology, Medical University of Warsaw, Warsaw, Poland.

Radosław Lenarczyk (R)

First Department of Cardiology and Angiology, Silesian Centre for Heart Disease, Zabrze, Poland.

Zbigniew Kalarus (Z)

Department of Cardiology, DMS in Zabrze, Medical University of Silesia, Katowice, Poland.

Gregory Y H Lip (GYH)

Liverpool Centre for Cardiovascular Science, Liverpool Heart and Chest Hospital, University of Liverpool, Liverpool, UK.
Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.

Paweł Balsam (P)

First Department of Cardiology, Medical University of Warsaw, Warsaw, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH